Rabbit Recombinant Monoclonal CYP3A7 antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IP | WB | IHC-P | ICC/IF | |
---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Select an associated product type
A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins during embryogenesis (PubMed:11093772, PubMed:12865317, PubMed:14559847, PubMed:17178770, PubMed:9555064). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:11093772, PubMed:12865317, PubMed:14559847, PubMed:17178770, PubMed:9555064). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes 3beta-hydroxyandrost-5-en-17-one (dehydroepiandrosterone, DHEA), a precursor in the biosynthesis of androgen and estrogen steroid hormones (PubMed:17178770, PubMed:9555064). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1), particularly D-ring hydroxylated estrone at the C16-alpha position (PubMed:12865317, PubMed:14559847). Mainly hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in atRA clearance during fetal development (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics including anticonvulsants (PubMed:9555064).
Cytochrome P450 3A7, CYPIIIA7, Cytochrome P450-HFLA, P450HLp2, CYP3A7
Rabbit Recombinant Monoclonal CYP3A7 antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
CYP3A7 also known as cytochrome P450 3A7 is an enzyme weighing approximately 57 kDa and belongs to the cytochrome P450 superfamily. This enzyme primarily facilitates the oxidation of various substrates including steroids fatty acids and xenobiotics. CYP3A7 expression is largely found in fetal liver tissue but shows decreased levels after birth. As part of the cytochrome P450 family CYP3A7 plays an important role in metabolic processes that modify and clear compounds from the body.
CYP3A7 acts on endogenous and exogenous molecules influencing steroid metabolism and drug catabolism. This enzyme acts individually rather than as part of a larger enzyme complex. Its function contributes significantly to the metabolism of retinoic acid and other steroid hormones during fetal development. The enzyme's substrate specificity enables it to play a role in modulating biological availabilities of several substances during prenatal human development.
CYP3A7's enzymatic activity integrates into the retinoic acid metabolism and steroid hormone biosynthesis pathways. It's actively involved in processing compounds needed for proper fetal growth and development such as all-trans-retinoic acid. Its relatives like CYP3A4 and CYP3A5 perform similar roles in adults showing high homology and overlapping substrate ranges reflecting their functional association within these pathways.
Researchers link CYP3A7 to alterations in drug metabolism affecting pharmacokinetics and therapeutic outcomes. For instance the enzyme's atypical activity can influence glucocorticoid metabolism connecting it to disorders like congenital adrenal hyperplasia. CYP3A7's function can also interact with proteins such as CYP21A2 further impacting steroidogenesis-related diseases. Understanding variations in CYP3A7 activity contributes to insights into certain congenital disorders and can guide personalized approaches in drug therapy.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-CYP3A7 antibody [EPR10650(2)(B)] (ab169764) at 1/1000 dilution
All lanes: Human fetal liver lysate at 10 µg
All lanes: Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 58 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com